232 related articles for article (PubMed ID: 33951990)
1. The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies.
Lei YY; Yeo W
Expert Opin Drug Saf; 2021 Oct; 20(10):1163-1175. PubMed ID: 33951990
[No Abstract] [Full Text] [Related]
2. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
[TBL] [Abstract][Full Text] [Related]
3. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
Lambertini M; Moore HCF; Leonard RCF; Loibl S; Munster P; Bruzzone M; Boni L; Unger JM; Anderson RA; Mehta K; Minton S; Poggio F; Albain KS; Adamson DJA; Gerber B; Cripps A; Bertelli G; Seiler S; Ceppi M; Partridge AH; Del Mastro L
J Clin Oncol; 2018 Jul; 36(19):1981-1990. PubMed ID: 29718793
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
Del Mastro L; Ceppi M; Poggio F; Bighin C; Peccatori F; Demeestere I; Levaggi A; Giraudi S; Lambertini M; D'Alonzo A; Canavese G; Pronzato P; Bruzzi P
Cancer Treat Rev; 2014 Jun; 40(5):675-83. PubMed ID: 24360817
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer.
Huang Y; Huang X; Huang X; Lin S; Luo S; Gu D; Weng X; Xu X
Hum Reprod; 2023 Jun; 38(6):1099-1110. PubMed ID: 37075316
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.
Lambertini M; Boni L; Michelotti A; Magnolfi E; Cogoni AA; Mosconi AM; Giordano M; Garrone O; Arpino G; Poggio F; Cinacchi P; Bighin C; Fregatti P; Pronzato P; Blondeaux E; Del Mastro L;
J Natl Cancer Inst; 2022 Mar; 114(3):400-408. PubMed ID: 34850043
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients.
Conte B; Del Mastro L
Minerva Ginecol; 2017 Aug; 69(4):350-356. PubMed ID: 28398024
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
Chen H; Xiao L; Li J; Cui L; Huang W
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
[TBL] [Abstract][Full Text] [Related]
11. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
[TBL] [Abstract][Full Text] [Related]
12. Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
Lambertini M; Del Mastro L; Viglietti G; Pondé NF; Solinas C; de Azambuja E
Curr Treat Options Oncol; 2017 Jan; 18(1):4. PubMed ID: 28185173
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
[TBL] [Abstract][Full Text] [Related]
14. Medical approaches to preservation of fertility in female cancer patients.
Del Mastro L; Giraudi S; Levaggi A; Pronzato P
Expert Opin Pharmacother; 2011 Feb; 12(3):387-96. PubMed ID: 21254946
[TBL] [Abstract][Full Text] [Related]
15. Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial.
Zong X; Yu Y; Yang H; Chen W; Ding X; Liu S; Li X; Chen X; Jiang C; Xia X; Huang R; Zhu M; Hu J; Liang C
JAMA Oncol; 2022 Feb; 8(2):252-258. PubMed ID: 34967844
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for premenopausal patients with early breast cancer.
Kurebayashi J
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006
[TBL] [Abstract][Full Text] [Related]
17. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.
Lambertini M; Cinquini M; Moschetti I; Peccatori FA; Anserini P; Valenzano Menada M; Tomirotti M; Del Mastro L
Eur J Cancer; 2017 Jan; 71():25-33. PubMed ID: 27940355
[TBL] [Abstract][Full Text] [Related]
18. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application.
Lambertini M; Horicks F; Del Mastro L; Partridge AH; Demeestere I
Cancer Treat Rev; 2019 Jan; 72():65-77. PubMed ID: 30530271
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis.
Li ZY; Dong YL; Cao XZ; Ren SS; Zhang Z
Menopause; 2022 Sep; 29(9):1093-1100. PubMed ID: 35917530
[TBL] [Abstract][Full Text] [Related]
20. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.
Yang B; Shi W; Yang J; Liu H; Zhao H; Li X; Jiao S
Breast; 2013 Apr; 22(2):150-157. PubMed ID: 23298851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]